Integer (ITGR) investor relations material

Market trends and positioning

• No significant trend toward insourcing; outsourcing remains preferred due to technical expertise and speed to market advantages.

• Strong industry leadership with global manufacturing scale and focus on delivering value as a dedicated CDMO.

• Deep integration and broad relationships with major OEMs drive heightened external interest.

• Customer concentration risk is mitigated by hundreds of programs across top med tech companies and a diversified portfolio.

• Pipeline has grown 300% since 2017, with 80% focused on faster-growing markets.

Strategic review and outlook

• Board initiated a strategic review due to increased external interest, with Goldman as advisor; all options being considered to maximize shareholder value.

• Timeline for review is months, not years, and outcome is open-ended.

• Standalone strategy remains viable if it best serves shareholder interests.

• Review timing driven by current high interest, not by market conditions.

Financial performance and guidance

• Q1 performance met expectations, with strength in both CV and CR product lines.

• Lowered guidance attributed mainly to reduced customer forecasts for electrophysiology (EP) products, reflecting inventory adjustments after rapid PFA adoption.

• Adjustments are considered short-term and not due to share loss or insourcing.

• More than half of the guidance reduction is EP-related, with additional risk adjustment applied.

• PMA portfolio expected to maintain 15%-20% CAGR, supported by new product launches and a robust customer base.